Genmab — Maj 2014
-
no of iss studies to be presented
-
for GEN investors asco will be a FAR MORE important event for dara
-
incredibly important for dara!!!!!!!
-
head to head firs
-
maintenance read out summer early fall
-
head2head må være lige på trapperne!!!
-
nu bowers
-
arzerra studier med small molecules - er på trapperne
-
der bliver noget fnidder omkring novartis antitrust og GSK
-
men gsk siger studies still on schedule
-
novartis må ikek blande sig
-
jan tænker at emea vil give den brede label- feedback very positive
-
very hopefull good outcome
-
håber på godkendelse immediately after summer
-
dara fase III'er quickly - certainly faster than anticipated
-
dara i monoterapi going - in rocket speed!!!
-
2014 WILL BE THE YEAR OF DATA FOR DARATUMUMAB
-
we hope to see other studies starting in addition to the ones already
-
potentially also in other indications than MM
-
altså i år.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind